MX2022012809A - Peptido para el tratamiento del sindrome de la tormenta de citocinas. - Google Patents
Peptido para el tratamiento del sindrome de la tormenta de citocinas.Info
- Publication number
- MX2022012809A MX2022012809A MX2022012809A MX2022012809A MX2022012809A MX 2022012809 A MX2022012809 A MX 2022012809A MX 2022012809 A MX2022012809 A MX 2022012809A MX 2022012809 A MX2022012809 A MX 2022012809A MX 2022012809 A MX2022012809 A MX 2022012809A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- increase
- composition
- hyperinflammation
- cytokine storm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica que comprende el péptido tipo APL identificado como SEQ ID NO:1, como inhibidor de un estado de hiperinflamación caracterizado por un aumento de citocinas o interleucinas y moléculas inflamatorias, que aumentan su concentración hasta alcanzar el estado definido como "tormenta de citocinas". Las concentraciones de sacarosa en dicha composición aumentan la actividad biológica del péptido, facilitando su aplicación por vía endovenosa. Dicho péptido en una composición farmacéutica es útil para la fabricación de un medicamento para tratar las enfermedades relacionadas con la hiperinflamación, tales como la Covid-19, el dengue, el síndrome de activación de macrófagos, la sepsis respiratoria y las asociadas a las terapias con células T, que poseen receptor de antígeno quimérico, y el síndrome de distrés respiratorio agudo. También revela un método para el tratamiento de dichas enfermedades, administrando una cantidad terapéuticamente efectiva de la composición.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000026A CU20200026A7 (es) | 2020-04-13 | 2020-04-13 | Péptido para el tratamiento del síndrome de la tormenta de citocinas |
| PCT/CU2021/050001 WO2021209080A2 (es) | 2020-04-13 | 2021-04-12 | Péptido para el tratamiento del síndrome de la tormenta de citocinas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012809A true MX2022012809A (es) | 2022-11-14 |
Family
ID=77338443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012809A MX2022012809A (es) | 2020-04-13 | 2021-04-12 | Peptido para el tratamiento del sindrome de la tormenta de citocinas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230190866A1 (es) |
| EP (1) | EP4137144A2 (es) |
| JP (1) | JP7737395B2 (es) |
| KR (1) | KR20220167289A (es) |
| CN (1) | CN115461069A (es) |
| AU (1) | AU2021256814A1 (es) |
| BR (1) | BR112022020442A2 (es) |
| CU (1) | CU20200026A7 (es) |
| MX (1) | MX2022012809A (es) |
| WO (1) | WO2021209080A2 (es) |
| ZA (1) | ZA202210315B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116355844B (zh) * | 2023-05-31 | 2023-08-18 | 吉林大学第一医院 | 一种SARS-CoV-2抗原诱发细胞因子风暴模型的建立及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003230181A1 (en) * | 2002-05-21 | 2003-12-02 | Yeda Research And Development Co. Ltd. | Dna vaccines encoding heat shock proteins |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| CU23701A1 (es) * | 2008-12-29 | 2011-09-21 | Ct Ingenieria Genetica Biotech | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
| WO2019069307A1 (en) * | 2017-10-06 | 2019-04-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | PEPTIDES FOR THE TREATMENT OF VIRAL INFECTIONS |
| CU24508B1 (es) * | 2017-12-29 | 2021-04-07 | Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma | Composición farmacéutica que comprende péptido tipo apl |
-
2020
- 2020-04-13 CU CU2020000026A patent/CU20200026A7/es unknown
-
2021
- 2021-04-12 WO PCT/CU2021/050001 patent/WO2021209080A2/es not_active Ceased
- 2021-04-12 US US17/918,299 patent/US20230190866A1/en active Pending
- 2021-04-12 CN CN202180027963.9A patent/CN115461069A/zh active Pending
- 2021-04-12 BR BR112022020442A patent/BR112022020442A2/pt unknown
- 2021-04-12 AU AU2021256814A patent/AU2021256814A1/en not_active Abandoned
- 2021-04-12 MX MX2022012809A patent/MX2022012809A/es unknown
- 2021-04-12 JP JP2022559505A patent/JP7737395B2/ja active Active
- 2021-04-12 EP EP21754903.9A patent/EP4137144A2/en active Pending
- 2021-04-12 KR KR1020227036582A patent/KR20220167289A/ko active Pending
-
2022
- 2022-09-16 ZA ZA2022/10315A patent/ZA202210315B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230190866A1 (en) | 2023-06-22 |
| BR112022020442A2 (pt) | 2023-01-17 |
| WO2021209080A3 (es) | 2022-04-07 |
| WO2021209080A2 (es) | 2021-10-21 |
| JP2023521592A (ja) | 2023-05-25 |
| EP4137144A2 (en) | 2023-02-22 |
| CA3172251A1 (en) | 2021-10-21 |
| JP7737395B2 (ja) | 2025-09-10 |
| AU2021256814A1 (en) | 2022-11-10 |
| CU20200026A7 (es) | 2021-11-04 |
| ZA202210315B (en) | 2023-07-26 |
| CN115461069A (zh) | 2022-12-09 |
| KR20220167289A (ko) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burgess et al. | The immune and regenerative response to burn injury | |
| Yahata et al. | Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury | |
| Uchida et al. | Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: implications in the development of neuropathic pain | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| AR117389A2 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer | |
| AR045710A1 (es) | Uso de inhibidores de tnf alfa y composiciones farmaceuticas que los comprenden para el tratamiento a dosis bajas | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| Efraim et al. | Roles of eosinophils in the modulation of angiogenesis | |
| AR063153A1 (es) | Anticuerpo monoclonal para prevenir/tratar el cancer | |
| PE20121687A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| BR112012033225A2 (pt) | análogos do glucagon | |
| MX2022001623A (es) | Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla. | |
| UY29321A1 (es) | Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de ácidos grasos | |
| Komine et al. | Mechanism of thymus-and activation-regulated chemokine (TARC)/CCL17 production and its modulation by roxithromycin | |
| CU20180039A7 (es) | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| NI201200085A (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| Karrer et al. | Cytokine-induced sleep: Neurons respond to TNF with production of chemokines and increased expression of Homer1a in vitro | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| MX2022011231A (es) | Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales. | |
| MX2024005237A (es) | Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo. | |
| Hussain et al. | Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies | |
| JP2019503341A5 (es) | ||
| CL2023003169A1 (es) | Alfa-1-antitripsina (aat) en el tratamiento y/o prevención de trastornos neurológicos | |
| Ciprandi et al. | Comano thermal water inhalations in the treatment of allergic rhinitis: preliminary results |